Skip to main content
Công ty Cổ phần Dược phẩm Imexpharm logo

Công ty Cổ phần Dược phẩm Imexpharm — Investor Relations & Filings

Ticker · IMP ISIN · VN000000IMP0 HSX Manufacturing
Open in API
Filings indexed 381 across all filing types
Latest filing 2025-09-24 Regulatory Filings
Country VN Viet Nam
Listing HSX IMP

About Công ty Cổ phần Dược phẩm Imexpharm

www.imexpharm.com

Imexpharm Corporation is a prominent pharmaceutical company with over 48 years of experience in the manufacturing, compounding, and distribution of high-quality pharmaceutical products. The company operates extensive production facilities, including three EU-GMP certified factory clusters and one WHO-GMP certified cluster, making it a leader in EU-GMP compliant manufacturing. Imexpharm is recognized as a top producer of antibiotics and offers a diverse product portfolio encompassing injectable and oral antibiotics, cardiovascular, ophthalmic, musculoskeletal, respiratory, and digestive system treatments, alongside vitamins, minerals, and health protection foods. With 28 product registrations for 11 products in Europe, Imexpharm is dedicated to delivering effective and safe healthcare solutions to the community.

Recent filings

Filing Released Lang Actions
IMP: Thông báo ngày ĐKCC lấy ý kiến cổ đông bằng văn bản
Regulatory Filings Classification · 85% confidence The document is a formal notice to the Vietnam Securities Depository (VSDC) announcing the record date for exercising shareholder rights. It is not financial results, director changes, dividend declarations, or a full report; rather, it’s a compliance/regulatory announcement about a corporate action (record date for written resolutions). This fits the “Regulatory Filings” fallback category (RNS).
2025-09-24 Vietnamese
IMP: Thông báo giao dịch cổ phiếu của Người nội bộ Trần Thị Đào
Director's Dealing Classification · 95% confidence The document is a formal notice filed with the State Securities Commission and Stock Exchange by an insider (the Director/General Director) disclosing his personal share transactions (number of shares held before and after, transaction type, purpose, period, etc.). This matches the definition of Director's Dealing (insider trading/reporting of personal share transactions by company executives).
2025-09-10 Vietnamese
IMP: Thông báo Quyết định của Cục thuế về việc xử phạt vi phạm hành chính về thuế qua kiểm tra thuế
Regulatory Filings Classification · 85% confidence The document is an irregular disclosure made by Imexpharm to the State Securities Commission and Ho Chi Minh City Stock Exchange regarding a Tax Department Decision imposing administrative penalties for tax violations. It is not a financial performance report, earnings release, or management presentation, nor is it a share transaction or dividend notice. Instead, it is a regulatory announcement of a legal/administrative action (tax penalty decision) and the company’s compliance measures. This falls under general regulatory filings.
2025-09-05 Vietnamese
IMP: Nghị quyết HĐQT về việc thực hiện quyền mua đối với Phương án phát hành cổ phiếu cho CĐHH của Agimexpharm
Share Issue/Capital Change Classification · 85% confidence The document is a stock exchange disclosure of a Board of Directors resolution to authorize the General Director to vote on and exercise subscription rights under a share issuance plan for existing shareholders of an associate company. This is not a financial report but an announcement regarding a share issuance and resulting capital change, matching the definition of a Share Issue/Capital Change filing.
2025-08-15 Vietnamese
IMP: Báo cáo tình hình quản trị công ty 06 tháng đầu năm 2025
Governance Information Classification · 90% confidence The document is a detailed corporate governance report for the first half of 2025, including the company’s governance model, Board of Directors composition, meeting timelines, resolutions, and internal governance activities. It is the full report itself (not merely an announcement) and matches the Governance Information definition.
2025-07-28 Vietnamese
IMP: Quyết định của HĐQT về việc miễn nhiệm Người nội bộ
Board/Management Information Classification · 98% confidence The document is a Regulatory 24-hour disclosure by Imexpharm Corporation announcing a Board of Directors decision to dismiss the Deputy General Director cum CFO. It details the management change, cites the BOD resolution and effective date, and is clearly an announcement of senior management changes. Therefore, it falls under ‘Board/Management Information’.
2025-07-21 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.